GenSight Biologics Reports Cash Position as of December 31, 2022, FY 2022 Revenues and Provides Business Update

GenSight Biologics to Present at Upcoming Investor Conferences

GenSight Biologics secures €12 Million financing through a premium convertible notes issuance to an institutional investor and provides business update

GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy

GenSight Biologics Announces Publication of Results of LUMEVOQ® REFLECT Pivotal Clinical Trial in Peer-Reviewed Journals

GenSight Biologics secures a €35 million credit facility from the European Investment Bank to support the launch of LUMEVOQ® in Europe

GenSight Biologics Reports Cash Position and Revenues as of September 30, 2022

GenSight Biologics to Present at Upcoming 2022 Medical Conferences

GenSight Biologics to Present at Upcoming Industry and Investor Conferences

GenSight Biologics Announces Successful Completion of LUMEVOQ® Engineering Batch Validating Implemented Corrective Actions